I just spoke with my broker. If you do nothing...that will be assumed you are accepting Option 1.
I am doing nothing..our shares are worth virtually nothing today.
I have never been through this either...would like to see an intelligent response with reasons.
The most recent SEC document was Scott Holmes options priced 100,000 shares at $7.66/share
exercisable on 7/27/2016...
Read SEC filings...or sign up on the KERX website under investor relations and they will email updates as they happen. Do your own DD.
I just sold 1/2 of my position at less than $7/share.. I have been holding shares for a long time..sold some at $15 and then bought back in around $10...bad move.
Management (and I use that term loosely) has not proven to be effective at sales stategies, communication or anything else.
The cheerleaders on the Board (i.e. Sadie et al) have been blaming market manipulators and the Easter Bunny for the freefall of the pps. Look no further than the top line called Revenue.
I am truly disgusted.
~ck (only 1/2 wrong and long)
DNDN had an approved prodcut on the market...know your facts.
The IPO price of NK the other day was $25..it went way up after that.
Very speculative stock...overvalued, too.
I am familiar with the founder from his previous deals. Not sure he is a genius or a snake oil salesman.
It is not hard to find info on this company..they rang the NASDAQ bell after the IPO.
back to the real deal...TTPH.
No one was worrying...just stating the price when someone didn't think TTPH would be in the $46s again.
No need for CAPS either.
Totally agree with your analysis of the situation.
The scripts are the only thing that matters and they do not show growth.
The cheerleaders can paint this anyway they want, but the only thing that counts is numbers.
~ck (long and watching profit evaporate)
I am considering buying some shares.
I am familiar with high optic pressure. I had PDS after cataract surgery and it caused a drainage blockage therefore raising my OP to dangerous levels. The second tim eit was worse.
How does this compare to combigan, alphagan or others?
Thank you in advance.
At least Holmes comes from AMAG.. that stock went from 17 to 77 and AMAG is actually profitable.
Perhaps he will bring some savvy to this lackluster management team.
He was controller of KERX back in the day.
I have been a shareholder for a long time and this is one of my biggest losers. My original cost is too high to even talk about.
I have not followed the science for awhile (I own too many biotechs) and would appreciate any updates about the status of their research.
I am hoping there is some light at the end of the tunnel. The stock price is in the tank...
Something good this way comes.
I think given the price action and the new hire announcement of Dumas, we have solid Ph III data coming sooner rather than later.
~ck (wish I had more shares)
Sentiment: Strong Buy
Just announed this morning there will be an earnings conference on July 31 at 8AM to discuss June results.
They will also be giving drug/FDA updates...could be interesting and a big day.
~ck (very long)
Sentiment: Strong Buy
They are a partner with CYTK on Omecamtiv:
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics holds the exclusive right to develop and commercialize tirasemtiv throughout the world. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. Amgen holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics' specified development and commercialization participation rights.
Sentiment: Strong Buy
Life is full of disappointments: HZNP response to poison pill:
We are very disappointed that instead of listening to its shareholders and immediately entering into negotiations with Horizon, the Depomed Board has instead taken actions to limit its shareholders' opportunity to maximize the value of their investment by implementing a poison pill and adopting changes to their bylaws that would, among other things, enable their Board of Directors to delay and make more difficult the calling of a special meeting of its shareholders. Horizon's proposal represents a premium of 42 percent to the closing price of Depomed's stock on July 6, 2015 and will yield significant strategic and financial benefits to shareholders of both companies. We urge the Depomed Board to stop taking actions to frustrate the will of their shareholders and engage with us to negotiate a mutually acceptable transaction."
There has been a poison pill put into place by DEPO:
Depomed Inc. ( DEPO
) disclosed Monday that it has taken steps to shield itself from a hostile takeover, about a week after Horizon Pharma PLC ( HZNP
) took its proposal to buy the company for $1.75 billion public.
In a securities filing, Depomed ( DEPO
) said it has adopted a poison-pill plan that would be triggered by a person or group acquiring a more than 10% stake in the company. A poison pill, or shareholder rights plan, is designed to dilute the value of stock by flooding the market with additional shares, making it more difficult for an investor to acquire a controlling stake.
Horizon said last week that it made the offer to buy Depomed ( DEPO
) in a letter sent May 27, but that Depomed ( DEPO
) had rejected the proposal. Horizon said it went public with its offer because Depomed ( DEPO
) executives have refused to engage in talks with Horizon.
In response, Depomed's ( DEPO
) board stated that the proposal was "not in the best interest" of the company, given that it is in a period of "significant growth" and is expected to benefit from its recent acquisition of the painkiller Nucynta from Janssen Pharmaceuticals Inc., a unit of Johnson & Johnson.